SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

@article{Advani2014SWOGSA,
  title={SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.},
  author={Anjali S. Advani and Shannon L McDonough and Steven E. Coutr{\'e} and Brent M. Wood and Jerald L Radich and Martha Mims and Margaret O'donnell and Stephanie L Elkins and Michael C. Becker and Megan K. D. Othus and Frederick R Appelbaum},
  journal={British journal of haematology},
  year={2014},
  volume={165 4},
  pages={504-9}
}
Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody against CD22, to the combination of clofarabine and cytarabine in adults with relapsed/refractory pre-B ALL. The response rate [complete remission and complete remission with incomplete count recovery… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS